Tumor News and Research

RSS

Advances in the field of MPI: an interview with Professor Kannan Krishnan

In around 2004, there was a Phillips paper that discussed a new imaging technique called MPI. At that time, I had an eager, promising graduate student named Matt Ferguson who wanted a project, so I asked him to take a look.

From Bruker BioSpin - NMR, EPR and Imaging 1 Mar 2016

Elevated levels of particular proteins in cancer cells fuel growth and spread of different cancers

Researchers at University of California, San Diego School of Medicine and Moores Cancer Center, with colleagues in Spain and Germany, have unraveled how elevated levels of particular proteins in cancer cells trigger hyperactivity in other proteins, fueling the growth and spread of a variety of cancers.

27 Feb 2016

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

Radiotherapy effectively damages brain tumors but the cancer cells can repair themselves in order to live on. Now, researchers at Sidney Kimmel Cancer Center have tested a strategy that combines radiotherapy with a drug that shuts down the ability of tumor to mend themselves.

27 Feb 2016

Researchers develop new method to screen tumor samples for presence of human polyomaviruses

Human polyomaviruses are commonly found in the population and generally do not produce noticeable symptoms. However, one type of human polyomavirus, the Merkel cell polyomavirus, is known to cause a rare form of skin cancer called Merkel cell carcinoma, and other members of the polyomavirus family can induce non-cancer related diseases in people with compromised immune systems.

27 Feb 2016

Light reflectance spectroscopy may lead to real-time tissue analysis during prostate cancer surgery

Researchers at UT Southwestern Medical Center have determined that light reflectance spectroscopy can differentiate between malignant and benign prostate tissue with 85 percent accuracy, a finding that may lead to real-time tissue analysis during prostate cancer surgery.

27 Feb 2016

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

Novartis today announced that the United States Food and Drug Administration approved Afinitor (everolimus) tablets for the treatment of adult patients with progressive, well-differentiated, nonfunctional neuroendocrine tumors (NET) of gastrointestinal (GI) or lung origin that are unresectable, locally advanced or metastatic.

26 Feb 2016

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

AbbVie, a global biopharmaceutical company, today announced the European Medicines Agency has granted Orphan Drug Designation to venetoclax, an investigational, oral B-cell lymphoma-2 (BCL-2) inhibitor, for the treatment of acute myeloid leukemia (AML).

26 Feb 2016

New analytical tool may help diagnose cancer faster than conventional methods

Researchers have developed a new analytical tool for medical applications and biological research that might be used to diagnose cancer more rapidly than conventional methods.

26 Feb 2016

Neurosurgeons use laser probe to deliver chemotherapy drugs to patients with glioblastoma

Using a laser probe, neurosurgeons at Washington University School of Medicine in St. Louis have opened the brain's protective cover, enabling them to deliver chemotherapy drugs to patients with a form of deadly brain cancer.

26 Feb 2016

Research finding could lay foundation for more accurate diagnosis for rare childhood brain tumor

An international research team has identified four likely new subtypes of a rare brain tumor using molecular techniques that lay the foundation for more accurate diagnosis and tailored therapies for the hard-to-treat cancer. Scientists at St. Jude Children's Research Hospital and the German Cancer Research Center led the study, results of which appear today in the scientific journal Cell.

26 Feb 2016

Moffitt researchers develop novel therapeutic strategy to keep resistant cells in check

Despite numerous advances in oncology since the War on Cancer began, many patients develop resistance to standard therapies and eventually relapse. Moffitt Cancer Center researchers hope to improve treatment outcomes with development of a novel therapeutic strategy, called adaptive therapy, which is based on evolutionary principals and aims to keep resistant cells in check by maintaining a population of chemo-sensitive cells.

25 Feb 2016

UNC-Chapel Hill pharmacy researchers use skin cells to destroy brain tumors

In a first for medical science, University of North Carolina at Chapel Hill pharmacy researchers turn skin cells into cancer-hunting stem cells that destroy brain tumors known as glioblastoma - a discovery that can offer, for the first time in more than 30 years, a new and more effective treatment for the disease.

25 Feb 2016

New report reveals malignant brain tumors as most common cause of cancer-related deaths in young people

A new report published in the journal Neuro-Oncology and funded by the American Brain Tumor Association finds that malignant brain tumors are the most common cause of cancer-related deaths in adolescents and young adults aged 15-39 and the most common cancer occurring among 15-19 year olds.

25 Feb 2016

Four molecular subtypes of pancreatic cancer identified

Today, researchers from the Australian Pancreatic Cancer Genome Initiative published a pivotal study in the journal Nature that identified four subtypes of pancreatic cancer.

25 Feb 2016

Investigating mechanism behind development of high-grade serous ovarian cancer

Rutgers Cancer Institute of New Jersey researcher Michael L. Gatza, PhD, has received a $747,000 Pathway to Independence Award (R00-CA166228) from the National Cancer Institute to explore the mechanism behind the development of a subtype of ovarian cancer known as high-grade serous ovarian cancer.

24 Feb 2016

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Asterias Biotherapeutics, Inc. today announced the successful completion of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for AST-VAC1, its investigational therapy targeting acute myeloid leukemia (AML).

24 Feb 2016

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Cancer immunology is based upon boosting the body's own immune system to vanquish malignancies. It is among the fastest growing areas of oncology research. Researchers at UC San Diego Moores Cancer Center have launched three clinical trials to test the safety and efficacy of a novel cellular-immunotherapy that uses modified T cells - one of the immune system's primary weapons - to treat three different types of blood cancer that often defy existing therapies.

24 Feb 2016

Immunotherapy emerges as promising strategy for treatment of brain tumors

For decades most cancers have been treated with a core standard of treatments that include surgery, radiation, and chemotherapy. Now, immunotherapy—a type of treatment that harnesses the patient's immune system to combat the disease—represents the future of cancer treatment, with its efficacy being demonstrated in even the most aggressive types of cancer.

24 Feb 2016

Gamma Knife and RapidArc equally effective at eradicating cancer in the brain

While two advanced radiosurgery approaches — Gamma Knife and RapidArc — offer different strengths, they are equally effective at eradicating cancer in the brain, say researchers at Sidney Kimmel Cancer Center.

24 Feb 2016

Maryland Proton Treatment Center completes first patient treatment with Varian ProBeam system

Varian Medical Systems, today announced the Maryland Proton Treatment Center successfully completed its first patient treatment with the Varian ProBeam system. The MPTC at the University of Maryland BioPark in West Baltimore houses five treatment rooms and is the first in the Eastern US to offer image-guided intensity-modulated proton therapy (IMPT) with a ProBeam system.

24 Feb 2016

Tumor News and Research

Advances in the field of MPI: an interview with Professor Kannan Krishnan

Elevated levels of particular proteins in cancer cells fuel growth and spread of different cancers

Radiotherapy plus panobinostat more effective for aggressive, recurrent brain cancer

Researchers develop new method to screen tumor samples for presence of human polyomaviruses

Light reflectance spectroscopy may lead to real-time tissue analysis during prostate cancer surgery

Novartis announces FDA approval of Afinitor for progressive, nonfunctional neuroendocrine tumors of GI

EMA grants Orphan Drug Designation to venetoclax for treatment of acute myeloid leukemia

New analytical tool may help diagnose cancer faster than conventional methods

Neurosurgeons use laser probe to deliver chemotherapy drugs to patients with glioblastoma

Research finding could lay foundation for more accurate diagnosis for rare childhood brain tumor

Moffitt researchers develop novel therapeutic strategy to keep resistant cells in check

UNC-Chapel Hill pharmacy researchers use skin cells to destroy brain tumors

New report reveals malignant brain tumors as most common cause of cancer-related deaths in young people

Four molecular subtypes of pancreatic cancer identified

Investigating mechanism behind development of high-grade serous ovarian cancer

Asterias announces successful completion of End-of-Phase 2 meeting with FDA for AML therapy

Researchers launch clinical trials to test novel cellular-immunotherapy to treat three types of blood cancer

Immunotherapy emerges as promising strategy for treatment of brain tumors

Gamma Knife and RapidArc equally effective at eradicating cancer in the brain

Maryland Proton Treatment Center completes first patient treatment with Varian ProBeam system

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Exploring the G:Box and for high-quality imaging

Latest News